Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03069482 · ClinicalTrials.gov registry record · Phase 1
Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT03069482 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 63 participants.
The verdict
NCT03069482, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
Quitting smoking has important health benefits for people with serious mental illness, more than half of whom are smokers. Smoking reductions in this population, in turn, could contribute to saving billions of dollars in healthcare expenditures. Finding ways to deliver more effective and wider reaching smoking cessation interventions to individuals with serious mental illness is a pressing priority. Smartphone apps are a wide reaching technology that could provide a viable platform to deliver smoking cessation interventions for individuals with serious mental illness. However, do smoking cessation apps need to be tailored for people with serious mental illness to ensure their success? Or can providers simply use standard and freely available smoking cessation mobile health treatments designed for the general population? Furthermore, is it feasible to conduct mHealth trials in this population? Therefore, this trial will test whether (1) a tailored smoking cessation app for people with serious mental illness results in higher levels of engagement with smoking cessation content as compared to an app designed for the general population and (2) smoking cessation mHealth trials can be feasibly conducted in this population.
Interventions
- DRUG Nicotine patch
- DRUG Nicotine lozenge
- DEVICE Learn to Quit App
- BEHAVIORAL Technical Coaching
- DEVICE NCI QuitGuide App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2019-01-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03069482
The ClinicalTrials.gov registry entry for NCT03069482 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Nicotine patch is the first listed.
NCT03069482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03069482 about?
NCT03069482 is a clinical study titled "Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness". Quitting smoking has important health benefits for people with serious mental illness, more than half of whom are smokers. Smoking reductions in this population, in turn, could contribute to saving billions of dollars in healthcare expenditures. Finding ways to deliver more effective and wider reac...
What is the current status of trial NCT03069482?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2017-05-15. Estimated completion is 2019-01-17.
What interventions are being tested in trial NCT03069482?
The interventions under investigation include: Nicotine patch (DRUG), Nicotine lozenge (DRUG), Learn to Quit App (DEVICE), Technical Coaching (BEHAVIORAL), NCI QuitGuide App (DEVICE).
Who is sponsoring clinical trial NCT03069482?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.